A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Clinical Rheumatology

• Publication date

  2019-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10067-018-04406-zPMID 30628014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• One year in review 2018: novelties in the treatment of rheumatoid arthritis.

  2018cited by this paper
• Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

  2018cited by this paper
• The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms

  2017cited by this paper
• Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

  2017cited by this paper
• Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

  2017cited by this paper
• Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

  2017cited by this paper
• Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

  2017cited by this paper
• Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis

  2017cited by this paper
• Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

  2017cited by this paper
• 2016 update of the EULAR recommendations for the management of early arthritis

  2016cited by this paper
• Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

  2016cited by this paper
• Rheumatoid arthritis

  2016cited by this paper
• Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

  2016cited by this paper
• The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents

  2016cited by this paper
• Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).

  2016cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

  2016cited by this paper
• Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques

  2016cited by this paper
• Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

  2016cited by this paper
• Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

  2015cited by this paper
• The therapeutic window of opportunity in rheumatoid arthritis: does it ever close?

  2015cited by this paper
• Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis

  2015cited by this paper
• A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

  2014cited by this paper
• Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

  2014cited by this paper
• Tight control applied to the biological therapy of rheumatoid arthritis.

  2013cited by this paper
• Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?

  2013cited by this paper
• Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis

  2013cited by this paper
• Different effects of biological drugs in rheumatoid arthritis.

  2013cited by this paper
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

  2013cited by this paper
• Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

  2012cited by this paper
• Epidemiology and burden of illness of rheumatoid arthritis

  2012cited by this paper
• Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

  2012cited by this paper
• Use of Mixed Treatment Comparisons in Systematic Reviews

  2012cited by this paper
• The Need to Better Classify and Diagnose Early and Very Early Rheumatoid Arthritis

  2012cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

  2010cited by this paper
• Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.

  2009cited by this paper
• Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef

  2009cited by this paper
• Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

  2009cited by this paper
• Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

  2008cited by this paper
• Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

  2008cited by this paper
• Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.

  2007cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal: Results From a Twelve-Month Randomized, Double-blind, Placebocontrol

  2006cited by this paper
• Quality of life in rheumatoid arthritis

  2005cited by this paper
• Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro

  2005cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

  2003cited by this paper
• Why we need a broad perspective on meta-analysis. It may be crucially important for patients.

  2000cited by this paper
• Why we need a broad perspective on meta-analysis

  2000cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Metabolism of ethylmalic acids by Pseudomonas aeruginosa.

  1968cited by this paper

• Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis

  2025cites this paper
• Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023

  2024cites this paper
• Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023.

  2024cites this paper
• Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis

  2023cites this paper
• Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study

  2023cites this paper
• A computational method for small molecule-RNA binding sites identification by utilizing position specificity and complex network information

  2023cites this paper
• The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis

  2022cites this paper
• Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis

  2022cites this paper
• Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

  2021cites this paper
• A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study

  2021cites this paper
• A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents

  2021cites this paper
• Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection

  2021cites this paper
• Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

  2021cites this paper
• Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

  2020cites this paper
• Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta‐analysis of randomized controlled trials

  2020cites this paper
• Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta‐analysis of randomized controlled trials

  2019cites this paper
• ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis

  2019cites this paper
• Think autoimmunity, breath autoimmunity, and learn autoimmunity

  2019cites this paper
• Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

  2018cites this paper